Wall Street Zen cut shares of Jasper Therapeutics (NASDAQ:JSPR – Free Report) from a hold rating to a sell rating in a research note published on Saturday,Wall Street Zen reports.
Other analysts also recently issued research reports about the company. Piper Sandler assumed coverage on Jasper Therapeutics in a research note on Wednesday, August 12th. They issued an “overweight” rating and a $60.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Jasper Therapeutics in a research report on Tuesday, August 18th. William Blair began coverage on Jasper Therapeutics in a research note on Wednesday, October 14th. They set an “outperform” rating for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $220.00.
Get Our Latest Stock Analysis on JSPR
Jasper Therapeutics Stock Performance
Shares of JSPR opened at $11.77 on Friday. The stock has a market cap of $13.06 million, a PE ratio of -0.25 and a beta of 3.30. Jasper Therapeutics has a fifty-two week low of $9.45 and a fifty-two week high of $72.60. The firm’s 50-day simple moving average is $16.60 and its two-hundred day simple moving average is $23.97.
Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last released its earnings results on Monday, November 16th. The company reported ($10.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.77) by ($8.42). Equities research analysts predict that Jasper Therapeutics will post -28.98 EPS for the current year.
About Jasper Therapeutics
Jasper Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies for conditions involving blood-forming stem cells and mast cells. Its research focuses on c-Kit, also known as CD117, a protein found on these cells. The company’s lead investigational drug, briquilimab (formerly JSP191), is a monoclonal antibody that targets c-Kit. Jasper has studied briquilimab as a conditioning treatment for stem cell transplantation and gene therapy, and is evaluating it for mast cell-mediated diseases, including chronic spontaneous urticaria.
See Also
- Five stocks we like better than Jasper Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
